FORTE BIOSCIENCES INC
FBRXNASDAQUS Equity
$654.00▼ $50.16 (−7.67%)
Simulated price1h—
24h▼ 7.7%
7d—
14d—
30d—
1y—
🏦Market Cap
$254.96B
Large Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
42
Weak
No chart data available for FBRX.
Trading Snapshot
- Day Range
- $650.37 – $665.51
- 52-Week Range
- —
- Volume
- $3.06B
- Avg Volume
- $3.97B
- Shares Outstanding
- —
- Next Earnings
- Oct 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $34.93B
- Last Q Revenue
- $8.38B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own FBRX
- ✓High-growth profile — revenue up +3.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$34.93B▲ +5.8% YoY
Gross Margin (TTM)
44.8%▲ +2.3% YoY
Operating Income (TTM)
$10.23B▲ +5.8% YoY
Free Cash Flow (TTM)
$6.15B▲ +5.8% YoY
About FORTE BIOSCIENCES INC
A company profile for FORTE BIOSCIENCES INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
42/100
Analyst Price Target
ⓘAverage Target
$713.77
▲ +9.1% Upside
High Target$887.98
Low Target$554.50
Based on 39 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
FORTE BIOSCIENCES INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift FBRX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
FORTE BIOSCIENCES INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.